The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/ fluticasone propionate (SFC) is well tolerated in patients with COPD over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006
Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality: INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations) study Source: Eur Respir J 2007; 30: Suppl. 51, 34s Year: 2007
The TORCH (TOwards a Revolution in COPD Health) survival study protocol Source: Eur Respir J 2004; 24: 206-210 Year: 2004
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
LATE-BREAKING ABSTRACT: Effect of fluticasone furoate (FF)/vilanterol (VI) on the rate of COPD exacerbations in everyday clinical practice: Results of the COPD Salford lung study (SLS) Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016
GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice Source: Eur Respir J 2002; 20: 819-825 Year: 2002
Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms & morning activities in COPD patients Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017
The correlation between asthma control and health status: the GOAL study Source: Eur Respir J 2007; 29: 56-62 Year: 2007
Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014